SCHEMBL3192272

SCHEMBL3192272

CCOc1ccc(N(Cc2cncs2)c2ccc(C(=O)O)cc2)cc1OCC

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
RXRA P19793 12/20 0.43
RXRB P28702 2/20 0.43
RXRG P48443 2/20 0.43
TSHR P16473 1/20 0.43
HRH4 Q9H3N8 1/20 0.42
POLB P06746 1/20 0.41
CASP6 P55212 1/20 0.41
TRPM8 Q7Z2W7 1/20 0.41
KDM4E B2RXH2 1/20 0.40
PPARG P37231 1/20 0.40
LMNA P02545 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
LTC4S Q16873 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3215147 0.95 TSHR (0.46) RXRARXRBRXRGTSHRHRH4
SCHEMBL3125823 0.95 TSHR (0.52) RXRARXRBRXRGTSHRHRH4
SCHEMBL3213511 0.92 RXRA (0.53) RXRARXRBRXRGHRH4TRPM8
SCHEMBL13486247 0.92 RXRA (0.53) RXRARXRBRXRGTSHRHRH4
SCHEMBL3125660 0.91 RXRA (0.42) RXRARXRBRXRGTSHRHRH4
SCHEMBL3214067 0.91 MRGPRX4 (0.42) RXRATSHRHRH4POLBCASP6
SCHEMBL3201995 0.87 HRH4 (0.39) TSHRHRH4TRPM8KDM4ELTC4S
SCHEMBL3211820 0.87 CA12 (0.45) RXRARXRBRXRGTSHRPOLB
SCHEMBL3123721 0.86 TSHR (0.49) TSHRHRH4POLBCASP6TRPM8
SCHEMBL3131869 0.84 TSHR (0.46) RXRARXRBRXRGTSHRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B RXRA 2856/4885RXRB 2676/4885RXRG 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.